Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.31 |
| ▸ | GSK3A | P49840 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23923109 | 0.70 | P2RX3 (0.36) | — | |
| SCHEMBL15357764 | 0.66 | CNR1 (0.32) | GSK3AGSK3B | |
| SCHEMBL21670417 | 0.63 | CYP11B2 (0.48) | — | |
| SCHEMBL24614004 | 0.62 | SMN1; SMN2 (0.39) | HCAR3GSK3AGSK3B | |
| SCHEMBL26248647 | 0.62 | ADORA2A (0.55) | HCAR3GSK3AGSK3B | |
| SCHEMBL16503635 | 0.62 | CNR1 (0.36) | HCAR3GSK3AGSK3B | |
| SCHEMBL15723732 | 0.61 | PDE3B (0.33) | KDM4E | |
| SCHEMBL24328037 | 0.60 | CYP11B2 (0.50) | HCAR3 | |
| SCHEMBL12543160 | 0.60 | HCAR3 (0.42) | KDM4EHCAR3GSK3AGSK3B | |
| SCHEMBL21670414 | 0.60 | KDM4E (0.31) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12071434-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-08-27 | — | — | US | disclosed |
| EP-3895707-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2023-10-04 | — | — | EP | disclosed |
| US-20230042358-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-02-09 | — | — | US | disclosed |
| EP-3895707-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2021-10-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230042358-A1 | HETEROCYCLIC COMPOUND | HCRTR2, HCRTR1, NTSR2 | KDM4E 1355/4885HCAR3 82/4885GSK3A 4606/4885 |
| US-12071434-B2 | Heterocyclic compound | HCRTR2, HCRTR1, NTSR2 | KDM4E 1355/4885HCAR3 82/4885GSK3A 4606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.